| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424455000 | Containing emulsions, dispersions, or solutions | 82 |
| 20080199516 | Encapsulation Of Lipid-Based Formulations In Enteric Polymers - A microcapsule comprising a lipid-based core that is encapsulated in an enteric polymer shell providing enhanced bioavailability of a sparingly water-soluble drug as well as modulated release of the drug, wherein the microcapsule is, in one embodiment, prepared by a centrifugal coextrusion process. The lipid-based core comprises lipidic carriers, either liquid or solid (melting point<1000C), that would provide adequate drug solubilization and is compatible with the enteric shell materials. | 08-21-2008 |
| 20080233185 | Fumaric Acid Derivatives as NF-kappaB Inhibitor - The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB. | 09-25-2008 |
| 20080241234 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof. | 10-02-2008 |
| 20080260815 | Multiparticulates - Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit® RSPO, a plasticising excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit® RLPO. The obtained multiparticulates show a release rate profile which is pH-independent. | 10-23-2008 |
| 20080260816 | Particulate Lipid Pharmaceutical Composition - A particulate lipid pharmaceutical composition comprises a particulate solid non-lipid carrier and an oil-in-water emulsion on the carrier. The emulsion comprises a dissolved or dispersed pharmacologically active agent. The oil-in-water emulsion is released from the carrier on contact with an aqueous media to form an oil-in-water emulsion in the media. Also disclosed is a method of producing the composition and a tablet containing it; sachets and capsules filled with the composition; use of the composition and the tablet as a medicine; a method of administering the composition to a patient. | 10-23-2008 |
| 20080279928 | Method for Producing Ultrafine Submicronic Suspensions - The invention concerns a method for producing ultrafine suspensions, characterized in that a substance in the form of a solid product at 20° C. is dissolved in a solvent, in that the solvent is very rapidly substantially drawn from said solution, in that the powder thus obtained, whereof the particles have an average particle-size distribution of the order of 1 to 50 μm (by laser diffractometry) is dispersed in a dispersing medium, and in that the resulting suspension is treated subsequently, using average to high forces, so as to obtain a suspension whereof the solid matter particles have a average particle-size distribution (by photon correlation spectroscopy) less than 3 μm, preferably less than 1 μm (1000 nm), and in particular less than 400 nm, more particularly still, less than 200 nm. | 11-13-2008 |
| 20090004261 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOLE-3-CARBOXAMIDE DERIVATIVE - this invention discloses and claims a pharmaceutical composition in liquid or semi-liquid form, which is self-emulsifying or self-microemulsifying in aqueous medium, for the oral administration of a pyrazole-3-carboxamide derivative, in which said derivative is dissolved in an amphiphilic mixture containing one or more lipid solvents and a nonionic hydrophilic surfactant. | 01-01-2009 |
| 20090047341 | CAPSULES OF CORE/SHELL TYPE AND PREPARATION PROCESS - The present invention relates to a process for the preparation of a suspension of capsules of core/shell type comprising the steps of mixing, at ambient temperature, an oily phase and polymers, at least one of which is an oligomer having a weight-average molecular weight of less than 10 000 and a hydroxyl number (N | 02-19-2009 |
| 20090053305 | Pharmaceutical Formulations - Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water. | 02-26-2009 |
| 20090130198 | PHARMACEUTICAL COMPOSITION WITH ENHANCED BIOAVAILABILITY - The invention pertains to a self-emulsifying pharmaceutical composition containing a lipophilic drug, a surfactant, and a hydrophilic carrier. The invention also provides a method for making the pharmaceutical composition for increasing the bioavailability of a drug by self-emulsification. | 05-21-2009 |
| 20090130199 | Preparations, Methods And Kits Useful For The Treatment of Cough - The invention relates to a respiratory preparation providing cough relief in a human comprising: a film forming agent; a thickening agent; and the respiratory preparation provides on demand relief. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a film forming agent; a thickening agent; and wherein said respiratory preparation provides on demand cough relief as needed. | 05-21-2009 |
| 20090155355 | Particles in a capsule - The invention relates to a capsule containing a heterogeneous mixture of active agents in the form of particles suspended in a liquid matrix and optionally active ingredients in the liquid matrix; the liquid matrix occupying less than the total internal volume of the capsule. The present invention further describes a capsule to allow the controlled-release of one or more active agents for specific desired benefits. | 06-18-2009 |
| 20090232885 | Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer; the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt.% of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—paddles@ 50 RPM and a two-stage dissolution medium at 37° C., (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8). | 09-17-2009 |
| 20090238866 | CHEWABLE CAPSULES - The invention provides an orally administrable chewable capsule comprising a capsule shell enclosing an oil-in-water emulsion in which the aqueous phase is gelled, or an oil droplet-containing dried residue of such an emulsion. | 09-24-2009 |
| 20090238867 | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same - Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections. | 09-24-2009 |
| 20090246275 | Compositions and methods for delivery of embolics - Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations. | 10-01-2009 |
| 20090252788 | Balsalazide formulations and manufacture and use thereof - The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide. | 10-08-2009 |
| 20090304788 | ENCAPSULATED MATERIALS AND METHODS FOR ENCAPSULATING MATERIALS - A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution. Additional embodiments are disclosed. | 12-10-2009 |
| 20090324711 | Oral Pharmaceutical Composition of Anilinopyrimidine, Preparation and Use Thereof - An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML. | 12-31-2009 |
| 20100062057 | Formulation - Novel capsules comprising a marine oil in an outer shell comprising alginate are disclosed. Also disclosed are methods of preparing the novel capsules and uses of thereof. | 03-11-2010 |
| 20100086587 | HARD SHELL CAPSULE FORMULATIONS - Hard shell capsules filled with a normally hygroscopic formulation and a method for producing the same is described. The hard shell capsules are filled with a normally hygroscopic formulation including, for example, an excipient, and optionally an active compound. The water content of the formulation and the hard shell capsule are in equilibration, and the formulation is hydrated by an amount selected to control equilibrium between said formulation and the hard shell capsule, and to provide a structurally stable hard shell capsule. The active compound may be a protein or peptide. | 04-08-2010 |
| 20100136105 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS - The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants. | 06-03-2010 |
| 20100143462 | NEW CARBAMAZEPHINE FORMULATIONS HAVING INPROVED SOLUBILITY - The present invention relates to pharmaceutical compositions in the form of microcmulsions comprising carbamazcpinc and their enhanced permeability and extended release properties. The microcmulsion composition may be an oil based formulation or a oil/aqueous phase mixed formulation. | 06-10-2010 |
| 20100196467 | THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL/BENAZEPRILAT - The present invention especially relates to the use of a combination comprising | 08-05-2010 |
| 20100203121 | FORMATION OF NANOMETRIC CORE-SHELL PARTICLES HAVING A METAL OXIDE SHELL - A process for preparing nanocapsules having a core-shell structure, comprising: | 08-12-2010 |
| 20100209496 | LIQUID AND SEMI-SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A SUBSTITUTED AMIDE - 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (Compound I) has surprisingly improved solubility, bioavailability and stability in an ampiphilic vehicle that can include propylene glycol, a propylene glycol sparing agent, an antioxidant, or a mixture thereof. In one embodiment of the present invention is a solution comprising the active or a pharmaceutically acceptable salt or solvate thereof, and an amphiphilic agent, said amphiphilic agent being a fatty acid ester of glycerol, propylene glycol or sorbitol. | 08-19-2010 |
| 20100215736 | ORAL DOSAGE FORM PROVIDING FAST ADSORPTION OF DRUG - The invention relates to a certain oral dosage form providing absorption of the drug diclofenac in an ultrafast manner. | 08-26-2010 |
| 20100247635 | PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME - A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake. | 09-30-2010 |
| 20100260835 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent dispersed therein. | 10-14-2010 |
| 20100291200 | FORMULATIONS FOR POORLY SOLUBLE DRUGS - The present invention provides a drug delivery system comprising nanoparticles or microparticles of a water poorly soluble drug dispersed in a polymeric bead containing essentially only of hydrophilic polymers (i.e. without hydrophobic polymers). The present invention further provides a method of producing the drug delivery system of the invention. | 11-18-2010 |
| 20100297221 | PHARMACEUTICAL COMPOSITION OF TACROLIMUS - An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection. | 11-25-2010 |
| 20100297222 | METHOD FOR PRODUCTION OF MICROCAPSULES USING SOLID FAT - A method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production, is provided. A method for production of S/O type microcapsules including the steps of: (1) emulsifying and dispersing a mixture of a solid fat and an aqueous solution containing a hydrophilic bioactive substance at a temperature of at least the melting point of the solid fat to obtain a W/O emulsion; (2) removing moisture in the W/O emulsion at a temperature of at least the melting point and lower than the boiling point of the solid fat to obtain an S/O suspension; (3) adding the S/O suspension into an aqueous phase containing at least one selected from a surfactant (B), a thickening agent and a hydrophilic organic solvent, and permitting liquid droplet dispersion at a temperature of at least the melting point and lower than the boiling point of the solid fat to obtain an S/O/W emulsion; and (4) cooling the S/O/W emulsion to lower than the melting point of the solid fat to harden the solid fat, and further removing the moisture at a temperature lower than the melting point of the solid fat. | 11-25-2010 |
| 20100297223 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION - A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4. | 11-25-2010 |
| 20100303901 | ORAL DELIVERY OF PROTEINS AND PEPTIDES - Enteric coated capsules or tablets for oral delivery of a protein, polypeptide or peptide drug, in particular for oral delivery of insulin, are provided, comprising microparticles of the protein, polypeptide or peptide drug, microparticles of a protease inhibitor and, optionally, microparticles of an absorption enhancer. The protease inhibitor and the absorption enhancer may be together in the same microparticles. The microparticles of each component are embedded in an enteric polymer matrix. The enteric coated tablet or capsule of the invention enables fast release of the protein, polypeptide or peptide drug at different times at desired loci in the gastrointestinal tract | 12-02-2010 |
| 20110059167 | ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS - The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment. | 03-10-2011 |
| 20110236476 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders. | 09-29-2011 |
| 20110262534 | POLYSACCHARIDE CAPSULE ENCLOSING A FATTY ACID OIL-CONTAINING EMULSION - Novel capsules where an outer shell comprises a polysaccharide, e.g. an alginate. In the capsules there is an emulsion comprising a fatty acid oil mixture and at least one surfactant. Preferred fatty acid oils are eicosapentaenoic acid (EPA) and doccosahexaenoic acid (DHA). | 10-27-2011 |
| 20110293714 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES - The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such. | 12-01-2011 |
| 20120039998 | PROCESS OF MANUFACTURING A STABLE SOFTGEL CAPSULE CONTAINING MICROENCAPSULATED PROBIOTIC BACTERIA - A softgel capsule containing microencapsulated probiotic bacteria is manufactured such that the softgel capsule is stable for at least about 24 months at room temperature. | 02-16-2012 |
| 20120045507 | STABLE SOFT CAPSULE DOSAGE FORM FOR ACETYLSALICYLIC ACID - A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided. | 02-23-2012 |
| 20120156288 | MICROCAPSULES CONTAINING SALTS FOR FOOD PRODUCTS - A composition for delivering edible salts into food products via microcapsules having a protein-polysaccharide shell matrix and an edible salt-containing active material. A method of treating osteoporosis is also disclosed. | 06-21-2012 |
| 20120171285 | SUBSTANCES FOR REDUCING OCCURRENCE OF MAJOR CARDIAC EVENTS COMPRISING OMEGA-3 POLYUNSATURATED FATTY ACID OR DERIVATIVES THEREOF AND HIGH-MONACOLIN K CONTENT RED YEAST RICE EXTRACT - Medicaments and therapeutic compositions comprise (1) at least one polyunsaturated fatty acid, at least one pharmaceutically acceptable derivative of a polyunsaturated fatty acid or mixtures thereof and (2) Red Yeast Rice extract comprising about 0.8 wt.% or more monacolin K. One source of component (1) is fish oil. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject. | 07-05-2012 |
| 20120177732 | CONCENTRATION AND MENTAL PERFORMANCE AMPLIFYING FORMULATION - A concentration and mental performance amplifying formulation comprising | 07-12-2012 |
| 20120219619 | SUBSTANCES FOR REDUCING OCCURRENCE OF MAJOR CARDIAC EVENTS IN HUMANS - A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents. | 08-30-2012 |
| 20120237598 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 09-20-2012 |
| 20120258168 | METHODS AND COMPOSITIONS TO PROMOTE OCULAR HEALTH - Embodiments include a composition to promote ocular health and a method of treatment for a subject exposed to a source of oxidative or visual stress to the eye or having a degradation of the eye. The composition may include amounts of vitamin A, which includes beta-carotene; vitamin C; vitamin D; vitamin E; zinc; copper; selenium; non-vitamin A carotenoids, which include lutein and zeaxanthin; omega-3 fatty acids, which include eicosapentaenoic acid and docosahexaenoic acid; taurine; alpha lipoic acid; pine bark extract; astaxanthin; and Piper spp. extract. The method includes the step of administering to the subject a daily dose of a composition to promote ocular health. | 10-11-2012 |
| 20120321706 | NOVEL GASTRORETENTIVE DOSAGE FORMS OF POORLY SOLUBLE DRUGS - Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug. | 12-20-2012 |
| 20130058999 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN PEPTIDES - The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such. | 03-07-2013 |
| 20130071473 | COMPOSITION AND METHOD FOR TREATING ULCERS - The composition for the treatment of ulcers includes ground charcoal, ground mustard seed and an edible salt dissolved or suspended in an edible oil. A single effective therapeutic dosage of the composition includes approximately 4,000 mg of the ground charcoal, approximately 2,500 mg of the ground mustard seed, approximately 550 mg of the edible salt, and approximately 15 ml of the edible oil. The effective therapeutic dosage is delivered to the patient orally, and may be provided to the patient as a tablet or capsule, or as a liquid mixture. | 03-21-2013 |
| 20130089605 | Method for Preparation of Highly Pure Asiaticoside Composition from Centella Asiatica and a Method of Use Thereof - Disclosed is a commercially viable asiaticoside composition having at least 99% purity that is derived from plant | 04-11-2013 |
| 20130095178 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders. | 04-18-2013 |
| 20130129821 | Ubiquinol and Alpha Lipoic Acid Compositions - The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules. | 05-23-2013 |
| 20130287844 | Agrochemical Formulation Comprising Encapsulated Pesticide - The present invention relates to microcapsules comprising a polyurea shell and a core, which contains a pesticide, a water-immiscible solvent A and at least 5 wt % of an aprotic, polar solvent B, which has a solubility in water from 0.5 to 20 g/l at 20° C., based on the total weight of the solvents in the core. It further relates to microcapsules comprising a shell and a core, which contains a pesticide and 2-heptanone; to a method for preparing said mircocapsules; to an aqueous composition comprising said microcapsules; and to a method for controlling phytopathogenic fungi and/or undesired plant growth and/or undesired attack by insects or mites and/or for regulating the growth of plants, with said mircocapsules. | 10-31-2013 |
| 20130309300 | FORTIFICATION OF NUTRITIONAL PRODUCTS WITH OLIVE EXTRACTS CONTAINING HYDROXYTYROSOL AND HYDROXYTYROSOL FORTIFIED NUTRITIONAL PRODUCTS - The present invention relates to nutritional products containing hydroxytyrosol, particularly fond products (i.e.: fortified edible oils and fortified edible oil-containing products) and dietary supplements (i.e.: soft gel capsules containing fortified edible oils) with increased antioxidant capacity to be used as a source of hydroxytyrosol for preventing or treating cardiovascular diseases, plaque build-up in the arteries, arterial hypertension, and metabolic syndrome, thanks to the nutritional supply of an hydroxytyrosol rich composition. | 11-21-2013 |
| 20130323303 | DRUG CARRIER AND PREPARATION METHOD THEREOF - A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid. The components of the aqueous micelles are phospholipids and amphiphilic chitosan, and the aqueous micelles enclose an aqueous solution containing a drug. Furthermore, the method of preparing the drug carrier is also provided. Therefore, with the pharmaceutical advantages of lipid-based nanoparticle included low drug leakage and the ability of to overcome the multiple drug resistance, this new formulation were further incorporated with the chitosan and featured with high payload efficiency. The features could enhance intracellular concentration of anti-cancer drug and oral bioavailability. | 12-05-2013 |
| 20130344141 | CONCENTRATION AND MENTAL PERFORMANCE AMPLIFYING FORMULATION - A concentration and mental performance amplifying formulation comprising | 12-26-2013 |
| 20140004185 | PHARMACEUTICAL COMPOSITION | 01-02-2014 |
| 20140010870 | PHARMACEUTICAL FORMULATION COMPRISING INOSITOL - The present invention relates to a pharmaceutical composition comprising solutions, suspensions of dispersions of inositol, or an isomer thereof, in a vehicle comprising gelatin, glycerol or mixtures thereof. | 01-09-2014 |
| 20140044779 | Liquid Carrier for Oral Delivery of a Pharmacologically Active Agent - A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH | 02-13-2014 |
| 20140141076 | SOFT CAPSULE PREPARATION, COMPOSITION FOR SOFT CAPSULE PREPARATION, AND METHOD OF PRODUCING SOFT CAPSULE PREPARATION - The present invention provides: a soft capsule preparation which includes a self-emulsifying composition containing an oily component, an emulsifier, 8% by mass to 20% by mass of a polyhydric alcohol and 2.5% by mass to 5% by mass of water, and a capsule film containing 35% by mass to 50% by mass of a polyhydric alcohol and gelatin, in which capsule film the above-described self-emulsifying composition is encapsulated; a method of producing the soft capsule preparation; a composition for a soft capsule preparation, which is an intermediate product of the soft capsule preparation; and a self-emulsifying composition and a capsule film composition that are used in the composition for a soft capsule preparation. | 05-22-2014 |
| 20140234411 | SEAMLESS CAPSULE AND MANUFACTURING METHOD THEREFOR - The present invention is related to a seamless capsule which easily dissolves in the oral cavity etc. The present invention provides a seamless capsule comprising a capsule content solution, and a capsule shell enclosing the capsule content solution, wherein the capsule shell comprises a gelatin having a bloom value of 50 to 190 and wherein the seamless capsule has a capsule shell-dissolution time of 60 seconds or less when the dissolution time is determined by a disintegration test using water as a test solution. | 08-21-2014 |
| 20140255481 | Pharmaceutical Compositions for Oral Administration of Insulin Peptides - The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such. | 09-11-2014 |
| 20140302134 | FORMULATION FOR THE CONTROLLED RELEASE OF ONE OR SEVERAL SUBSTANCES IN THE DIGESTIVE TRACT OF A MAMMAL - The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value. | 10-09-2014 |
| 20140314840 | UBIQUINOL AND ALPHA LIPOIC ACID COMPOSITIONS - The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules. | 10-23-2014 |
| 20140335172 | OPHTHALMOLOGICAL RINSING AGENT AND METHODS THEREFOF - Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the eye cavity after ophthalmological procedures using the disclosed rinsing agent in order to prevent the development of long-term complications associated with the emulsified oil droplets. | 11-13-2014 |
| 20150017238 | METHODS AND COMPOSITIONS FOR TREATING DIABETES - Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue. | 01-15-2015 |
| 20150079164 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND VITAMIN D FOR ACNE VULGARIS AND/OR ECZEMA, AND METHODS AND USES THEREOF - The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis). | 03-19-2015 |
| 20150314000 | Pharmaceutically Acceptable Solubilizing Composition and Pharmaceutical Dosage Form Containing Same - Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake. | 11-05-2015 |
| 20150342881 | CURCUMIN SOLUBILISATE - A solubilisate composed of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm. | 12-03-2015 |
| 20160051484 | SUBSTANCE-CONTAINING VESICLE, AND PRODUCTION METHOD THEREFOR - Provided is a monodisperse agglomerate of a substance-containing vesicle filled with a substance at a concentration higher than conventionally possible. A mixed solution, in which a target substance is included in an aqueous medium, is mixed with a monodisperse agglomerate of a crosslinked vesicle comprising a prescribed polymer which includes a first polymer, i.e. a block copolymer having uncharged hydrophilic segments and first charged segments, and a second polymer having second charged segments carrying a charge opposite to that of the first charged segments, and in which the first polymer and/or the second polymer are/is crosslinked. As a result, the crosslinked vesicle is made to contain the target substance. | 02-25-2016 |
| 20160074322 | ORAL CEFEPIME COMPOSITIONS AND USES THEREOF - The invention features pharmaceutical compositions, methods, and kits including cefepime, or a pharmaceutically acceptable salt thereof and an additive including an acyl carnitine. The additive is present in an amount sufficient to increase the oral bioavailability of the cefepime. | 03-17-2016 |
| 20160081964 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 03-24-2016 |
| 20160081965 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin with a reduced dose. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 03-24-2016 |
| 20160089353 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 03-31-2016 |
| 20160090558 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS - The present invention relates to delivery systems comprising malodor reduction compositions, methods of making such delivery systems and consumer products made with such delivery systems. Such delivery systems do not unduely interfere with the scent of the perfumed or unperfumed delivery system, perfumed or unperfumed products comprising such delivery systems and any perfumed or unperfumed situs that is treated with such products. | 03-31-2016 |
| 20160128939 | CURCUMIN SOLUBILISATE - A solubilisate composed of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm. | 05-12-2016 |
| 20160151319 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID | 06-02-2016 |
| 20160166631 | NUTRACEUTICAL COMBINATION FOR PREVENTION AND TREATMENT OF TYPE 2 DIABETES | 06-16-2016 |
| 20160166635 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS | 06-16-2016 |
| 20160184238 | SOLUBILIZED CoQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules. | 06-30-2016 |
| 20160250157 | Tincture For Infusing Flavonoids And Methods Of Use | 09-01-2016 |
| 20180021386 | CORE-SHELL CAPSULES FOR ENCAPSULATION OF PARTICLES, COLLOIDS, AND CELLS | 01-25-2018 |
